Qiagen

Historical price data

Founded in 1984, QIAGEN has established itself as a foundational player in the life sciences tools and molecular diagnostics sector with a mission to 'make improvements in life possible.' The company's strategy is built on its integrated 'Sample to Insight' workflow solutions, serving diverse end markets from clinical diagnostics to pharmaceutical R&D. With a market cap of $8.13B and a broad portfolio, QIAGEN leverages its scale and technological breadth to drive growth in areas like digital PCR, next-generation sequencing (NGS), and syndromic testing.

Integrated 'Sample to Insight' platform encompassing technologies for sample preparation, assay technologies (PCR, dPCR, NGS), automation instrumentation, and bioinformatics software to extract and interpret molecular data from biological samples.

Competes with giants like Thermo Fisher and Roche in core reagent and instrument markets, with Bio-Rad in digital PCR, and with bioMérieux in syndromic testing. Its integrated workflow approach and strong brand in sample prep are key differentiators against more fragmented competitors.